Crizotinib or ceritinib, which drug is more suitable?

Crizotinib is a multi-target protease inhibitor mainly used to treat anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer. Crizotinib is the main targeted drug for ALK positive lung cancer and non-small cell cancer.

Ceritinib is a second-generation ALK inhibitor, and its inhibitory effect on ALK may be more powerful and precise. It is usually used in patients who have developed resistance to crizotinib or when treatment with crizotinib has failed.

Crizotinib According to clinical trials and practical applications, crizotinib can kill tumor cells in the lungs and has clear efficacy in most patients. The drug will not be discontinued until the disease progresses and becomes intolerable.

There are case reports showing that some patients who do not respond to initial treatment with crizotinib may benefit from subsequent treatment with otherALK inhibitors such as ceritinib.

In patients who are resistant or ineffective to crizotinib, ceritinib has shown significant therapeutic effects, especially in liver metastases. There are cases showing that ceritinib treatment achieves tumor regression, which is due to its better biological efficacy.

Common side effects of crizotinib include liver and kidney damage, interstitial pneumonia, visual abnormalities, nausea, vomiting, etc. Most adverse reactions are mild, relatively easy to overcome, and can be alleviated with drug treatment.

Ceritinib As a second-generation drug, ceritinib may have a different side effect profile and requires close attention to patient response.

When choosing crizotinib or ceritinib, doctors need to consider the patient's ALK status, severity of the condition, previous treatment history, and the patient's overall health. Crizotinib is usually the first choice for treatment-naive patients with ALK-positive non-small cell lung cancer. For patients who are resistant or ineffective to crizotinib, ceritinib may be an effective alternative.